Floatz logo

Imlifidase

Crigler-Najjar Syndrome

Genethonprotein_peptidePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Crigler-Najjar Syndrome cohort.

Asset / SponsorPhaseRating
gnt0003
Genethon
Phase 2CCC
VOLRUBIGENE RALAPARVOVEC
Audentes Therapeutics
Phase 1CC
Orlistat
University Medical Center Groningen
N/AD
Hepastem
Cellaion SA
Phase 1/2NR

Same molecule, other indications

Imlifidase is also rated in:

Duchenne muscular dystrophyDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →